Drugs /

simvastatin

Back to Drugs List

Overview

NCI Definition [1]:
A lipid-lowering agent derived synthetically from a fermentation product of the fungus Aspergillus terreus. Hydrolyzed in vivo to an active metabolite, simvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)

Clinical Trials

View Clinical Trials for simvastatin

Simvastatin has been investigated in 6 clinical trials, of which 6 are open and 0 are closed. Of the trials investigating simvastatin, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 4 are phase 2 (4 open).

ER Expression, ER Positive, and ERBB2 Amplification are the most frequent biomarker inclusion criteria for simvastatin clinical trials.

Breast adenocarcinoma, breast carcinoma, and invasive breast carcinoma are the most common diseases being investigated in simvastatin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Simvastatin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating simvastatin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
velastatin, 2,2-dimethylbutyric acid, 8-ester with (4r,6r)-6-(2-((1s,2s,6r,8s,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2h-pyran-2-one, [1s-[1alpha,3alpha,7beta,8beta(2s*,4s*),8abeta]]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl)ethyl]-1-naphthalenyl 2,2-dimethylbutanoate, simvastatin, simvastatin (substance), synvinolin, mk-733, mk733, simvastatinum, mk 733, simvastatine, zocor, simvastatin, simvastatina, synvinolin, zocor, simvastatin (product), simvastatin [chemical/ingredient]
NCIT ID [1]:
C29454
SNOMED ID [1]:
C-80812

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.